Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399032 | 1.00 | MAPT (0.47) | MAPTHCAR2ALDH1A1TSHRPPARD | |
| Butyric Acid SCHEMBL11237541 | 0.89 | HCAR2 (0.42) | MAPTHCAR2ALDH1A1TSHRPPARD | |
| SCHEMBL17398721 | 0.88 | MAPT (0.42) | MAPTHCAR2ALDH1A1TSHRPPARD | |
| SCHEMBL6231924 | 0.85 | HCAR2 (0.43) | MAPTHCAR2TSHRPPARDTTR | |
| SCHEMBL4978281 | 0.85 | HCAR2 (0.43) | MAPTHCAR2TSHRPPARDTTR | |
| SCHEMBL13502893 | 0.85 | MAPT (0.47) | MAPTHCAR2ALDH1A1TSHRTTR | |
| SCHEMBL6382885 | 0.85 | NPSR1 (0.40) | MAPTHCAR2ALDH1A1TSHRPPARD | |
| SCHEMBL6382879 | 0.85 | NPSR1 (0.40) | MAPTHCAR2ALDH1A1TSHRPPARD | |
| SCHEMBL8620959 | 0.84 | MAPT (0.46) | MAPTHCAR2ALDH1A1PPARDTTR | |
| SCHEMBL15163745 | 0.84 | MAPT (0.46) | MAPTHCAR2ALDH1A1TSHRTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 474 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2644612-B1 | Method for producing sanshool | TSUMURA & CO (JP) | 2016-01-06 | — | — | EP | claimed |
| US-8877953-B2 | Method for producing sanshool | TSUMURA & CO. (JP) | 2014-11-04 | — | — | US | claimed |
| US-20130261327-A1 | METHOD FOR PRODUCING SANSHOOL | TSUMURA & CO. (JP) | 2013-10-03 | — | — | US | claimed |
| EP-2644612-A1 | Method for producing sanshool | TSUMURA & CO. (JP) | 2013-10-02 | — | — | EP | claimed |
| JP-62129246-A | — | — | None | — | — | JP | disclosed |
| US-20260116838-A1 | NEOCARZILIN DERIVATIVES AS ANTIMETASTATIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025217121-A1 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2025-10-16 | — | — | WO | disclosed |
| US-4281019-A | 4-[(Unsaturated or cyclopropylated alkyl)amino]phenyl compounds useful as hypolipidemic and antiatherosclerotic agents | AMERICAN CYANAMID COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4259352-A | 4-[Cycloalkyl- or cycloalkenyl-amino(cycloalkyl- or cycloalkenyl-alkenyl)amino]phenyl compounds, useful as hypolipidemic and antiatherosclerotic agents | AMERICAN CYANAMID COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4226878-A | ANTIINFLAMMATORY, HYPOTENSIVES, ANTIHISTAMINES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1980-10-07 | — | — | US | disclosed |
| US-4211783-A | Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| US-4205085-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1980-05-27 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
| US-4107188-A | FOR DECREASING LIPID LEVELS | HOFFMANN-LA ROCHE INC. (US) | 1978-08-15 | — | — | US | disclosed |
| US-4053618-A | ANTILIPOLYTIC | ROUSSEL-UCLAF (FR) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261327-A1 | METHOD FOR PRODUCING SANSHOOL | SCO2, FTH1, CNKSR1 | MAPT 4345/4885HCAR2 1059/4885ALDH1A1 1678/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | MAPT 3706/4885HCAR2 4860/4885ALDH1A1 3351/4885 |
| US-20260116838-A1 | NEOCARZILIN DERIVATIVES AS ANTIMETASTATIC AGENTS | SLC75A1, SLC18A3, SLC8A1 | MAPT 1277/4885HCAR2 1249/4885ALDH1A1 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.